Arcus Biosciences(RCUS) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update Casdatifan (HIF-2a inhibitor) Casdatifan Updates: • Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting • Additional data from the ARC-20 cohorts evaluating casdatifan monothe ...